Literature DB >> 29637590

Cannabis for Chronic Pain: Challenges and Considerations.

E Alfonso Romero-Sandoval1, Jack E Fincham2, Ashley L Kolano2, Brandi N Sharpe2, P Abigail Alvarado-Vázquez1.   

Abstract

The National Academies of Sciences, Engineering, and Medicine has found substantial evidence that cannabis (plant) is effective for the treatment of chronic pain in adults, and moderate evidence that oromucosal cannabinoids (extracts, especially nabiximols) improve short-term sleep disturbances in chronic pain. The paradoxical superiority of the cannabis plant over cannabinoid molecules represents a challenge for the medical community and the established processes that define modern pharmacy. The expanding and variable legalization of cannabis in multiple states nationwide represents an additional challenge for patients and the medical community because recreational and medicinal cannabis are irresponsibly overlapped. Cannabis designed for recreational use (containing high levels of active ingredients) is increasingly available to patients with chronic pain who do not find relief with current pharmacologic entities, which exposes patients to potential harm. This article analyzes the available scientific evidence to address controversial questions that the current state of cannabis poses for health care professionals and chronic pain patients and sets the basis for a more open discussion about the role of cannabis in modern medicine for pain management. A critical discussion on these points, the legal status of cannabis, and considerations for health care providers is presented.
© 2018 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  marijuana; medical cannabis; medical marijuana; medicinal cannabis; medicinal marijuana; recreational cannabis; recreational marijuana

Mesh:

Substances:

Year:  2018        PMID: 29637590     DOI: 10.1002/phar.2115

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  19 in total

1.  High-Frequency Medical Cannabis Use Is Associated With Worse Pain Among Individuals With Chronic Pain.

Authors:  Kevin F Boehnke; J Ryan Scott; Evangelos Litinas; Suzanne Sisley; David A Williams; Daniel J Clauw
Journal:  J Pain       Date:  2019-09-24       Impact factor: 5.820

2.  Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CB2 receptors in female, and CB1/CB2 receptors in male mice in an inflammatory pain model.

Authors:  Henry L Blanton; Agata Pietrzak; Melissa C McHann; Josée Guindon
Journal:  Brain Res Bull       Date:  2021-09-14       Impact factor: 4.077

Review 3.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

4.  Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.

Authors:  Cerina Lee; Jessica M Round; Scott Klarenbach; John G Hanlon; Elaine Hyshka; Jason R B Dyck; Dean T Eurich
Journal:  Harm Reduct J       Date:  2021-06-08

5.  Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.

Authors:  Jennifer S Gewandter; Shannon M Smith; Robert H Dworkin; Dennis C Turk; Tong J Gan; Ian Gilron; Sharon Hertz; Nathaniel P Katz; John D Markman; Srinivasa N Raja; Michael C Rowbotham; Brett R Stacey; Eric C Strain; Denham S Ward; John T Farrar; Kurt Kroenke; James P Rathmell; Richard Rauck; Colville Brown; Penney Cowan; Robert R Edwards; James C Eisenach; McKenzie Ferguson; Roy Freeman; Roy Gray; Kathryn Giblin; Hanna Grol-Prokopczyk; Jennifer Haythornthwaite; Robert N Jamison; Marc Martel; Ewan McNicol; Michael L Oshinsky; Friedhelm Sandbrink; Joachim Scholz; Richard Scranton; Lee S Simon; Deborah Steiner; Kenneth Verburg; Ajay D Wasan; Kerry Wentworth
Journal:  Pain       Date:  2021-11-01       Impact factor: 7.926

Review 6.  Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors.

Authors:  Pietro Brunetti; Simona Pichini; Roberta Pacifici; Francesco Paolo Busardò; Alessandro Del Rio
Journal:  Medicina (Kaunas)       Date:  2020-05-15       Impact factor: 2.430

7.  Mapping cannabis potency in medical and recreational programs in the United States.

Authors:  Mary Catherine Cash; Katharine Cunnane; Chuyin Fan; E Alfonso Romero-Sandoval
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

8.  Cannabis alleviates neuropathic pain and reverses weight loss in diabetic neuropathic cachexia in a previous heroin abuser.

Authors:  Deeb Daoud Naccache
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-10-14

Review 9.  A narrative review of the ethnomedicinal usage of Cannabis sativa Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh.

Authors:  Shahriar S M Shakil; Matt Gowan; Kerry Hughes; Md Nur Kabidul Azam; Md Nasir Ahmed
Journal:  J Cannabis Res       Date:  2021-03-19

10.  Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.

Authors:  Cerina Lee; Mu Lin; Karen J B Martins; Jason R B Dyck; Scott Klarenbach; Lawrence Richer; Ed Jess; John G Hanlon; Elaine Hyshka; Dean T Eurich
Journal:  BMC Public Health       Date:  2021-05-01       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.